TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7484574

Group type: EXPERIMENTAL
Intervention: Globular enhancement on single-pass, contrast-enhanced CT scans
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Globular enhancement isodense relative to that of the aorta
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Nonglobular enhancement in metastases
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Diagnostic categorization of lesions
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Agreement in identification of globular enhancement
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Overall agreement in categorization of lesions
Number of subjects: 50
Study: 2147836

Group type: EXPERIMENTAL
Intervention: Dobutamine (D)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Enoximone (E)
Number of subjects: 40
Study: 7352483

Group type: EXPERIMENTAL
Intervention: Low-dose intravenous oxytocin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Low-dose prostaglandin F2 alpha (PGF2 alpha)
Number of subjects: 50
Study: 30069590

Group type: EXPERIMENTAL
Intervention: Polyaxial locking plate system
Number of subjects: 40

Group type: COMPARATOR
Intervention: Monoaxial locking plate system
Number of subjects: 40
Study: 28855452

Group type: EXPERIMENTAL
Intervention: Canrenone
Number of subjects: 413

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 413
Study: 25943350

Group type: EXPERIMENTAL
Intervention: Postoperative docetaxel-5FU regimen (D 85 mg/m2, day 1 and 5FU 750 mg/m2/day continuous infusion, days 1-5 every 3 weeks) after preoperative dose-intense epirubicin-cyclophosphamide (E 150 mg/m2 and C 4000 mg/m2 every 3 weeks) and locoregional treatment.
Number of subjects: 174

Group type: COMPARATOR
Intervention: Preoperative dose-intense epirubicin-cyclophosphamide (E 150 mg/m2 and C 4000 mg/m2 every 3 weeks) followed by mastectomy and radiotherapy.
Number of subjects: 174
Study: 24313906

Group type: EXPERIMENTAL
Intervention: Standardized exercise training (3 times per week for 12 weeks)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Standardized exercise training
Number of subjects: 93
Study: 22266683

Group type: EXPERIMENTAL
Intervention: Footrot vaccine (Footvax, MSD) plus targeted antibiotic therapy (long‐acting amoxicillin, Betamox LA, Norbrook Pharmaceuticals)
Number of subjects: 748

Group type: COMPARATOR
Intervention: Targeted antibiotic therapy only
Number of subjects: 748
Study: 19514186

Group type: EXPERIMENTAL
Intervention: Mind-tranquilizing and menstruation-regulating acupuncture method
Number of subjects: 40

Group type: COMPARATOR
Intervention: Routine acupuncture method
Number of subjects: 40
Study: 17804322

Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser at 1 W
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser at 1.5 W
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser at 1 W
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser at 1.5 W
Number of subjects: 60

Group type: COMPARATOR
Intervention: Comparison of Nd:YAG laser to Er,Cr:YSGG laser
Number of subjects: 60
Study: 15180967

Group type: EXPERIMENTAL
Intervention: Resistance exercise intervention using a flywheel ergometer (FWE) during bed rest.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no exercise intervention).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Resistance exercise intervention using a flywheel ergometer (FWE).
Number of subjects: 0
Study: 12491697

Group type: EXPERIMENTAL
Intervention: Naftopidil tablet 25 mg, p.o., qn for 42 days
Number of subjects: 80

Group type: COMPARATOR
Intervention: Tamsulosin 0.2 mg, p.o., qn for 42 days
Number of subjects: 80
Study: 9535521

Group type: EXPERIMENTAL
Intervention: Lateral translations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anterior/posterior translations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both lateral and anterior/posterior translations
Number of subjects: 0
Study: 7630674

Group type: EXPERIMENTAL
Intervention: Prednisone (2 mg/kg up to 60 mg)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 2621763

Group type: EXPERIMENTAL
Intervention: Stress inoculation training
Number of subjects: 18

Group type: COMPARATOR
Intervention: No stress management training (control)
Number of subjects: 18
Study: 31968177

Group type: EXPERIMENTAL
Intervention: CATCH My Breath program
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 12
Study: 30793493

Group type: EXPERIMENTAL
Intervention: Direct current cardioversion (DCCV)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Permanent pacemaker (PPM) + atrioventricular node ablation (AVNA) + DCCV
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: AF ablation
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 67
Study: 26581545

Group type: EXPERIMENTAL
Intervention: Emergent change implementation approach
Number of subjects: 0

Group type: COMPARATOR
Intervention: Planned change implementation approach
Number of subjects: 0
Study: 26431650

Group type: EXPERIMENTAL
Intervention: Human Urinary Kallikrein injection (0.15 PNA unit) plus 100 mL saline, intravenous infusion, once a day for 14 days
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Human Urinary Kallikrein injection for L subtype patients
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Human Urinary Kallikrein injection for S subtype patients
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Kallikrein treatment group
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 110
Study: 23806459

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate nasal spray (FFNS), 110 μg once daily
Number of subjects: 548

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 548
Study: 17049710

Group type: EXPERIMENTAL
Intervention: Biological threat stimuli (CS+) directed towards participants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cultural threat stimuli (CS+) directed towards participants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Biological threat stimuli (CS-) not directed towards participants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cultural threat stimuli (CS-) not directed towards participants
Number of subjects: 0
Study: 16279294

Group type: EXPERIMENTAL
Intervention: VDIS decision support system
Number of subjects: 7348

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 7348
Study: 11010937

Group type: EXPERIMENTAL
Intervention: Sucrose (n = 10)
Number of subjects: 21

Group type: COMPARATOR
Intervention: No sucrose (Control group, n = 11)
Number of subjects: 21
Study: 8971306

Group type: EXPERIMENTAL
Intervention: 7-day course of amoxycillin 1 g b.d., omeprazole 20 mg b.d. and clarithromycin 500 mg b.d.
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 10-day course of amoxycillin 1 g b.d., omeprazole 20 mg b.d. and clarithromycin 500 mg b.d.
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 14-day course of amoxycillin 1 g b.d., omeprazole 20 mg b.d. and clarithromycin 500 mg b.d.
Number of subjects: 150
Study: 1572756

Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 4064576

Group type: EXPERIMENTAL
Intervention: Naloxone (8 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Cold-pressor test (control)
Number of subjects: 6
Study: 31144591

Group type: EXPERIMENTAL
Intervention: Partial gland ablation (PGA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Objective performance criteria/goals (OPC/OPG)
Number of subjects: 0
Study: 26340920

Group type: EXPERIMENTAL
Intervention: Alcohol group (0.7 g/kg)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Non-alcohol group
Number of subjects: 87
Study: 25766455

Group type: EXPERIMENTAL
Intervention: Diet combined with 12 weeks of abdominal resistance training
Number of subjects: 40

Group type: COMPARATOR
Intervention: Diet only
Number of subjects: 40
Study: 22835498

Group type: EXPERIMENTAL
Intervention: Classification by heart rate (HR)
Number of subjects: 36504

Group type: EXPERIMENTAL
Intervention: Classification by systolic blood pressure (SBP)
Number of subjects: 36504

Group type: EXPERIMENTAL
Intervention: Patients with GCS=15
Number of subjects: 36504

Group type: EXPERIMENTAL
Intervention: Patients with GCS<12
Number of subjects: 36504
Study: 20935607

Group type: EXPERIMENTAL
Intervention: Intermuscular minimally invasive surgery (MIS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard lateral transmuscular approach
Number of subjects: 30
Study: 19330801

Group type: EXPERIMENTAL
Intervention: Caffeinated gum (40 mg)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 118

Group type: COMPARATOR
Intervention: No gum
Number of subjects: 118
Study: 17028353

Group type: EXPERIMENTAL
Intervention: sublingual misoprostol 50 micrograms every 4 hours for up to five doses
Number of subjects: 50

Group type: COMPARATOR
Intervention: oxytocin infusion after artificial rupture of membranes
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: sublingual misoprostol
Number of subjects: 50
Study: 14970777

Group type: EXPERIMENTAL
Intervention: Pilocarpine
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Bethanechol
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Pilocarpine and Bethanechol
Number of subjects: 42
Study: 10905597

Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study: 9166301

Group type: EXPERIMENTAL
Intervention: Continuous closure with looped polyglyconate suture
Number of subjects: 614

Group type: COMPARATOR
Intervention: Interrupted closure with interrupted polyglycolic acid
Number of subjects: 614
Study: 8268429

Group type: EXPERIMENTAL
Intervention: Thoracic epidural analgesia
Number of subjects: 45

Group type: COMPARATOR
Intervention: Lumbar epidural analgesia
Number of subjects: 45
Study: 3754633

Group type: EXPERIMENTAL
Intervention: Tactile/kinesthetic stimulation (body stroking and passive movements of the limbs for three, 15-minute periods per day for 10 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (20 control neonates)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tactile/kinesthetic stimulation
Number of subjects: 20
Study: 31915511

Group type: EXPERIMENTAL
Intervention: Natural Vitamin B complex
Number of subjects: 30

Group type: COMPARATOR
Intervention: Synthetic Vitamin B complex
Number of subjects: 30
Study: 28977340

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention
Number of subjects: 1528

Group type: EXPERIMENTAL
Intervention: Self-reported PA
Number of subjects: 1528

Group type: EXPERIMENTAL
Intervention: Accelerometer CPMs
Number of subjects: 1528

Group type: COMPARATOR
Intervention: Health Education (HE)
Number of subjects: 1528
Study: 27028269

Group type: EXPERIMENTAL
Intervention: Oxycodone (10 mg extended release, 8 doses)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Venlafaxine (37.5 mg extended release, 8 doses)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 25156683

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 450

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 450
Study: 22292424

Group type: EXPERIMENTAL
Intervention: BetaSweet carrot juice
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Balero carrot juice
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Overall sample (carrot juice intake)
Number of subjects: 69
Study: 20724487

Group type: EXPERIMENTAL
Intervention: Smoothie containing 22.5 g blueberry bioactives
Number of subjects: 32

Group type: COMPARATOR
Intervention: Smoothie of equal nutritional value without added blueberry bioactives (placebo group)
Number of subjects: 32
Study: 18946063

Group type: EXPERIMENTAL
Intervention: Pulmonary‐vein isolation
Number of subjects: 81

Group type: COMPARATOR
Intervention: Atrioventricular‐node ablation with biventricular pacing
Number of subjects: 81
Study: 16088807

Group type: EXPERIMENTAL
Intervention: RIX4414 vaccine (3 concentrations: 10(4.7), 10(5.2), 10(6.1) focus-forming units)
Number of subjects: 2464

Group type: EXPERIMENTAL
Intervention: RIX4414 vaccine
Number of subjects: 2464

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2464
Study: 12834518

Group type: EXPERIMENTAL
Intervention: Composite intervention including a 3-hour continuing medical education course, training in management of UI, patient educational materials, and on-site physician and office support.
Number of subjects: 1145

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1145
Study: 10502364

Group type: EXPERIMENTAL
Intervention: Digestible fat
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Sucrose polyester
Number of subjects: 18

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 18
Study: 8698630

Group type: EXPERIMENTAL
Intervention: vindesine and cisplatin (VP)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: mitomycin C, vindesine and cisplatin (MVP)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 134
Study: 1928272

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 0.3% ophthalmic solution
Number of subjects: 148

Group type: COMPARATOR
Intervention: Standard therapy (fortified cefazolin 33 mg/ml and fortified gentamicin or tobramycin 14 mg/ml)
Number of subjects: 148
Study: 7153945

Group type: EXPERIMENTAL
Intervention: Positive expectancy group (n = 8)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Negative expectancy group (n = 8)
Number of subjects: 32
Study: 31699709

Group type: EXPERIMENTAL
Intervention: NY-ESO-1 protein with poly-ICLC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NY-ESO-1 protein with poly-ICLC and montanide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30982711

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine with Vatinoxan
Number of subjects: 6

Group type: COMPARATOR
Intervention: Vatinoxan alone
Number of subjects: 6
Study: 29037631

Group type: EXPERIMENTAL
Intervention: Bowen Therapy
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 34
Study: 26502357

Group type: COMPARATOR
Intervention: TAK-385 (0 [placebo], 80, 120, 180, or 360 mg) single doses
Number of subjects: 176

Group type: COMPARATOR
Intervention: TAK-385 (0, 20, 40, 80, or 180 mg) daily for 14 days
Number of subjects: 176

Group type: COMPARATOR
Intervention: TAK-385 (40 [with loading dose], 60, 80, or 160 mg) daily for 28 days
Number of subjects: 176

Group type: COMPARATOR
Intervention: Discontinuation of TAK‐385 on day 28
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: TAK-385 (40-180 mg/d)
Number of subjects: 176
Study: 24912901

Group type: EXPERIMENTAL
Intervention: Communication Skills Training (CST) program (2-day workshop)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 30
Study: 22383508

Group type: EXPERIMENTAL
Intervention: Oral ascorbic acid (Asc) 2-g single dose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19201328

Group type: EXPERIMENTAL
Intervention: Self-etching primer (SEP) - Transbond Plus, 3M Unitek, Monrovia, Calif
Number of subjects: 25

Group type: COMPARATOR
Intervention: Conventional etch and sealant (CES) - Light Bond, Reliance Orthodontic Products, Itasca, Ill
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Both groups (SEP and CES)
Number of subjects: 25
Study: 17543874

Group type: EXPERIMENTAL
Intervention: Dorzolamide
Number of subjects: 1077

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1077
Study: 15390067

Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 21

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 21
Study: 11453971

Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg daily for 12 weeks
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo treatment for 12 weeks
Number of subjects: 58
Study: 8158539

Group type: EXPERIMENTAL
Intervention: Aerosolized pentamidine (300 mg monthly)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Low-dose daily TMP-SMX (400-80 mg)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Aerosolized pentamidine
Number of subjects: 214

Group type: COMPARATOR
Intervention: Low-dose daily TMP-SMX
Number of subjects: 214
Study: 3414587

Group type: EXPERIMENTAL
Intervention: High-fat diet (46% of calories)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Low-fat diet (25% of calories)
Number of subjects: 6
Study: 31132542

Group type: EXPERIMENTAL
Intervention: First episode psychosis (FEP) smokers
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: Established psychosis smokers
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: Highly nicotine dependent smokers in established psychosis
Number of subjects: 613
Study: 27832717

Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 898

Group type: COMPARATOR
Intervention: Etanercept
Number of subjects: 898
Study: 25442784

Group type: EXPERIMENTAL
Intervention: Low intensity falls prevention education program
Number of subjects: 1206

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1206
Study: 23835543

Group type: EXPERIMENTAL
Intervention: Application of plastic wrap (NeoWrap) immediately after birth; infants encased from neck down without being dried, head dried with a prewarmed towel, and a hat added.
Number of subjects: 92

Group type: COMPARATOR
Intervention: Standard care (control group); infants transferred to prewarmed radiant warmer, dried, and warm towels and a hat applied.
Number of subjects: 92
Study: 21540865

Group type: EXPERIMENTAL
Intervention: Cilengitide (500, 1000 and 2000 mg) twice weekly with standard doses of cetuximab, cisplatin and 5-fluorouracil
Number of subjects: 10
Study: 18465410

Group type: EXPERIMENTAL
Intervention: Cochlear Implant (CI)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Hearing Aids (HAs)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Longer-term CI users
Number of subjects: 9

Group type: COMPARATOR
Intervention: HA-only users
Number of subjects: 9
Study: 16971235

Group type: EXPERIMENTAL
Intervention: Chlormadinone acetate (10 mg initially, reduced daily to 2 mg over 5 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (similar 5-day gradual reduction regimen)
Number of subjects: 0
Study: 14634172

Group type: EXPERIMENTAL
Intervention: Sondhi Rapid Set (SD) adhesive
Number of subjects: 40

Group type: COMPARATOR
Intervention: Maximum Cure (MC) adhesive
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sondhi Rapid Set (SD) adhesive (maxillary arch)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Maximum Cure (MC) adhesive (maxillary arch)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sondhi Rapid Set (SD) adhesive (mandibular arch)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Maximum Cure (MC) adhesive (mandibular arch)
Number of subjects: 40
Study: 10663358

Group type: COMPARATOR
Intervention: HRT (piperazine estrone sulfate 0.625‐0.937 mg daily +/‐ medroxyprogesterone acetate 2.5 mg daily)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: HRT plus calcitriol (0.25 microg twice daily)
Number of subjects: 71

Group type: COMPARATOR
Intervention: HRT
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: HRT plus calcitriol
Number of subjects: 71
Study: 8640974

Group type: EXPERIMENTAL
Intervention: [13N]ammonia
Number of subjects: 30

Group type: COMPARATOR
Intervention: [15O]water
Number of subjects: 30
Study: 1889777

Group type: EXPERIMENTAL
Intervention: Eyes with PEX
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 164
Study: 6498792

Group type: EXPERIMENTAL
Intervention: Selenium (96 micrograms/day)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Vitamin E (300 mg/day)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Selenium and Vitamin E combination
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 3514154

Group type: EXPERIMENTAL
Intervention: Lactate 12 percent lotion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Petrolatum-based creme (creme B)
Number of subjects: 0
Study: 29076786

Group type: EXPERIMENTAL
Intervention: Adenosine-induced cardiac arrest (AiCA)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Temporary clipping (TC)
Number of subjects: 130
Study: 26492924

Group type: EXPERIMENTAL
Intervention: Online haemodiafiltration (HDF)
Number of subjects: 2793

Group type: EXPERIMENTAL
Intervention: Online haemodiafiltration (HDF) with high delivered convection volume (>23 L per 1.73 m² BSA per session)
Number of subjects: 2793
Study: 23181455

Group type: EXPERIMENTAL
Intervention: DASH 2 wellness plus
Number of subjects: 23

Group type: COMPARATOR
Intervention: DASH 2 wellness only standard of care
Number of subjects: 23
Study: 22454089

Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine
Number of subjects: 2054

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2054
Study: 20942279

Group type: EXPERIMENTAL
Intervention: Acupoint catgut embedding treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Western medicine treatment (Tiopronin and Xuezhikang capsule)
Number of subjects: 60
Study: 18090872

Group type: EXPERIMENTAL
Intervention: Transdermal hormone therapy (estradiol: 0.72 mg/2 d)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oral hormone therapy (conjugated equine estrogens: 0.625 mg/d)
Number of subjects: 30
Study: 16829649

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 12653409

Group type: EXPERIMENTAL
Intervention: Lapsers
Number of subjects: 893

Group type: COMPARATOR
Intervention: Abstainers
Number of subjects: 893
Study: 10389805

Group type: EXPERIMENTAL
Intervention: Clonidine (4.5 microg/kg)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control (no clonidine)
Number of subjects: 104
Study: 8889115

Group type: EXPERIMENTAL
Intervention: 2 g creatine daily
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 2064291

Group type: EXPERIMENTAL
Intervention: Stapled anastomosis using GIA and TA staplers after right hemicolectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hand-sewn anastomoses after right hemicolectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stapled anastomosis after left colectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hand-sewn anastomoses after left colectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stapled anastomosis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hand-sewn anastomosis
Number of subjects: 0